Show Summary Details
Page of

Vigabatrin 

Vigabatrin
Chapter:
Vigabatrin
Author(s):

Andrea E. Cavanna

DOI:
10.1093/med/9780198791577.003.0015
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 13 October 2019

Vigabatrin is a second-generation antiepileptic drug characterized by a few antiepileptic indications, with a very good interaction profile in polytherapy. Clinically relevant adverse effects (especially visual field defects) have reduced its use as antiepileptic drug in routine clinical practice considerably. Vigabatrin has an acceptable behavioural tolerability profile, although patients with epilepsy treated with this medication can report depression, psychosis, and irritability. Risk factors for developing psychiatric adverse effects include high starting and maintenance doses, past psychiatric history, and epilepsy severity. Vigabatrin has no approved indications or clinical uses in psychiatry, despite weak evidence for its usefulness in the treatment of anxiety disorders and addictions.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.